Company: RCUS
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001724521-25-000063
Chunk: 210

Company: Arcus Biosciences, Inc.
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 1
Chunk 210
---
$— $— $1,005 Types of securities as of December 31, 2024AmortizedCostUnrealizedGainUnrealizedLoss FairValueMoney market funds$120 $— $— $120 U.S. treasury securities251 — — 251 Corporate securities and commercial paper592 — — 592 U.S. government agency securities5 — — 5 Certificate of deposit24 — — 24 Total cash, cash equivalents and marketable securities$992 $— $— $992 

16

The following table summarizes the fair values of our cash, cash equivalents and marketable securities by location in the Condensed Consolidated Balance Sheets and contractual maturity (in millions):Location in Condensed Consolidated Balance SheetsContractual MaturityMarch 31, 2025December 31, 2024Cash and cash equivalents—$192 $150 Marketable securitiesWithin one year805 828 Long-term marketable securitiesBetween one and three years8 14 Total cash, cash equivalents and marketable securities $1,005 $992 Realized gains or losses recognized on the sale of available-for-sale marketable securities were not material for the three months ended March 31, 2025 and 2024. Realized gains and losses are included in Interest and other income, net, in the Condensed Consolidated Statements of Operations. The cost of a security sold is determined using the specific-identification method.We limit the credit risk associated with our investments by placing them with banks and institutions we believe are highly credit worthy and investing in highly rated investments. We held a total of 71 and 54 positions in securities which were in unrealized loss positions as of March 31, 2025 and December 31, 2024, respectively, which were immaterial individually and in aggregate. We do not intend to sell our securities with unrealized loss positions and have concluded we will not be required to sell the securities before recovery of the amortized cost for the investment at maturity. No credit related losses have been recognized for any of the periods presented.The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the Condensed Consolidated Balance Sheets to the total shown in the Condensed Consolidated Statements of Cash Flows (in millions):As of March 31,20252024Cash and cash equivalents$192 $185 Restricted cash (included in Other non